Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Dr O’Reilly on the Potential of TTFields in Unresectable, Locally Advanced Pancreatic Cancer

August 11th 2025

Eileen M. O’Reilly, MD, discusses the potential of tumor treating fields for the treatment of patients with locally advanced pancreatic cancer.

Consensus on Clinical Trial End Points Is Essential for Improved Drug Development Across MPNs

August 11th 2025

Andrew Kuykendall, MD, outlines the limitations of current clinical end points and discusses the need for molecularly informed drug development in MPN.

Real-World Data Support Bevacizumab-Based Quadruplet Therapy in Frontline Advanced Cervical Cancer

August 8th 2025

Alberto Farolfi, MD, PhD, shares results from a real-world study of first-line bevacizumab, pembrolizumab, and platinum chemotherapy in cervical cancer.

From BTK Inhibitors to CAR T-Cell Therapies: Hematologic Malignancies Landscape Sees an ‘Explosion of New Therapies’

August 7th 2025

Kathleen A. Dorritie, MD, highlights important NCCN guideline updates and research to watch in hematologic malignancies.

Novel ADC Sigvotatug Vedotin Generates Early Efficacy in NSCLC

August 7th 2025

Rachel E. Sanborn, MD, discusses the novel IB6-directed ADC sigvotatug vedotin for the treatment of patients with NSCLC.

Shift Toward Chemotherapy-Free Approaches Redefines Upfront CLL Treatment Selection

August 6th 2025

Kathleen A. Dorritie, MD, discusses 2 clinical scenario cases to showcase differences in the management of newly diagnosed vs relapsed/refractory CLL.

Questions Arise As CAR T-Cell Therapy and Bispecific Antibody Use Increase in Relapsed/Refractory Myeloma

August 6th 2025

Prerna Mewawalla, MD, highlights sequencing strategies with CAR T-cell therapy and bispecific antibodies in managing relapsed/refractory multiple myeloma.

Serum KIM-1 Emerges as Potential Biomarker to Guide Adjuvant Immunotherapy in High-Risk Resected RCC

August 5th 2025

Sumanta Kumar Pal, MD, FASCO, discusses findings from a genomic analysis of patients with high-risk, resected RCC treated with checkpoint inhibitors.

Dr Dorritie on the Role of Quadruplet Regimens in Multiple Myeloma

August 5th 2025

Kathleen A. Dorritie, MD, discusses the role of quadruplet regimens for the treatment of patients with multiple myeloma.

Rising Incidences, Misconceptions, and Unmet Needs Warrant Awareness for Appendix Cancer

August 5th 2025

Rosario Ligresti, MD, FASGE, discusses the rising incidence of appendix cancer, lack of optimal treatment modalities, and unmet needs for these patients.

Dr Haas on Evolutions in Clinical Trial Design in the RCC Treatment Paradigm

August 4th 2025

Naomi B. Haas, MD, discusses previously conducted trials that supported the initiation of the KEYNOTE-564 trial of adjuvant pembrolizumab in RCC.

Dr George on the Clinical Relevance of Targetable Mutations in GIST

August 4th 2025

Suzanne George, MD, discusses the evolving development of targeted therapies for patients with gastrointestinal stromal tumor.

BXCL701 Plus Pembrolizumab is Safe and Generates Early Antitumor Activity in Advanced PDAC

August 4th 2025

Benjamin A. Weinberg, MD, FACP, discusses the potential role of BXCL701 plus pembrolizumab in advanced pancreatic ductal adenocarcinoma.

Dr McKay on the Role of Casdatifan Plus Cabozantinib in Clear Cell RCC

August 4th 2025

Rana R. McKay, MD, FASCO, details the significance of casdatifan plus cabozantinib demonstrating better responses vs the respective agents alone in ccRCC.

CaRe Prostate Study of INKmune in Metastatic CRPC Hits Primary, Secondary End Points

August 4th 2025

The phase 1/2 CaRe Prostate trial examining INKmune in patients with metastatic CRPC has met its primary and secondary end points.

EMA Grants PRIME Designation to BGB-16673 for Previously Treated Waldenström Macroglobulinemia

August 4th 2025

The BTK degrader BGB-16673 has received PRIME designation from the EMA for the treatment of patients with Waldenström macroglobulinemia.

ALPHA3 Trial of Cema-Cel in LBCL Proceeds With Fludarabine/Cyclophosphamide Lymphodepletion Regimen

August 4th 2025

Fludarabine plus cyclophosphamide lymphodepletion will be used in the phase 2 ALPHA3 trial of first-line consolidation cema-cel in patients with LBCL.

Consensus Guidelines Needed to Further Optimize PARP Inhibition, Molecular Imaging, and ARPI Use in Prostate Cancer Management

August 4th 2025

Rana R. McKay, MD, expands on key updates and knowledge gaps in prostate cancer management discussed at the Bridging the Gaps in Prostate Cancer meeting.

Oral SERDs and PI3K Inhibitors Move the Needle Beyond CDK4/6 Inhibitors in Metastatic Breast Cancer

August 1st 2025

Katherine C. Ansley, MD, discusses the role of oral SERDs and PI3K and AKT inhibitors for the treatment of metastatic breast cancer.

Dr Tan on the Ongoing Investigation of Adaptive Treatment Intensification Strategies in RCC

August 1st 2025

Alan Tan, MD, discusses current and future avenues for evaluating adaptive immunotherapy approaches in treatment-naive metastatic RCC.